All News
Filter News
Found 808,679 articles
-
Bob Harper and AstraZeneca Bring Virtual Series to Heart Attack Survivors to Inspire Others with Stories About Second Chances
7/15/2020
AstraZeneca today announced that Survivors Have Heart, a national community-building movement powered by stories of heart attack survivors and their loved ones, will return for its third year.
-
BioAtla Raises $72.5 Million In Series D Financing
7/15/2020
Proceeds will advance CAB-AXL and CAB-ROR2 clinical programs into Phase 2 trials, CAB-CTLA-4 Phase 1 trial, and additional CAB development programs
-
ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production
7/15/2020
ZYUS Life Sciences Inc. ("ZYUS"), a company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and cannabinoid-based formulations, announced today that it has reached a positive milestone in the development of COVID-19 vaccine components by achieving plant-based expression, isolation, and purification of a potential antigen for a SARS-CoV-2 vaccine - providing proof of concept for plant-based COVID-19 antigen production.
-
DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test
7/15/2020
DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus ™ SARS-CoV-2 Test
-
Blue Cross Blue Shield of Massachusetts Pilots New Value-Based Payment Program For Independent Primary Care Practices
7/15/2020
Makes AQC model, designed to improve quality and lower costs, available to smaller practices Also offers immediate support payment to practices that adopt model [15-July-2020] BOSTON , July 15, 2020 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) is launching an innovative program to improve the quality of patient care, slow the rise o
-
Arrakis Therapeutics Appoints Erik Spek, Ph.D., J.D., as Vice President, Legal and Intellectual Property
7/15/2020
Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Erik Spek, Ph.D., J.D., has joined the company as Vice President, Legal and Intellectual Property. Dr. Spek is an experienced biotech executive who has been a leader in corporate legal affairs and intellectual property for biotech companies, including Vedant
-
ICU Medical, Inc. Announces Time of Second Quarter 2020 Earnings Conference Call
7/15/2020
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its second quarter 2020 earnings release and conference call.
-
Relay Therapeutics Announces Pricing of Initial Public Offering
7/15/2020
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the pricing of its initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share
-
TI Health and Medisafe Partner to Extend 1st Party Patient Targeting Solutions
7/15/2020
Data-driven healthcare marketing leader TI Health has entered into a partnership with Medisafe, to further build out education and awareness opportunities for unique hand-raising patient targeting solutions for pharmaceutical companies.
-
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)
7/15/2020
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1) (8 yes; 7 no).
-
HealthEquity Announces Closing of Sale of Additional Shares
7/15/2020
HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”) today announced the closing of the underwritten public offering of an additional 690,000 shares of its common stock pursuant to the exercise in full by the underwriters of their over-allotment option
-
Theratechnologies Announces Financial Results for the Second Quarter of Fiscal 2020
7/15/2020
-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020- -Trogarzo ® net revenues up 13.2% and combined EGRIFTA ® , EGRIFTA SV ® net revenues up 7.3% over Q2 2019- -Supply chain and product inventory remain unaffected by COVID-19 pandemic- MONTREAL, July 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its
-
Karius Named to Forbes AI 50 List of Most Promising Artificial Intelligence Companies
7/15/2020
Karius, the world leader in liquid biopsy for infectious diseases, was named one of America's most promising artificial intelligence companies by Forbes.
-
BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
7/15/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with the investigational medicine infigratinib, an orally available small molecule, that targets the overactivity of fibroblast growth factor receptor 3 (FGFR3) in the PROPEL 2 Phase 2 clinical trial . Achondroplasia is the most common cause of disproportionate short stature.¹ “With preclinical evidence sh
-
Tiziana Life Sciences plc Change to ADS Ratio - Updated
7/15/2020
Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt ("ADR") programme.
-
Lyfebulb Seeks Companies with Solutions to Address Substance Use Disorders for an Innovation Challenge
7/15/2020
Lyfebulb, a patient empowerment platform, in partnership with Orexo, a global leader in the addictive disorders field, invites entrepreneurs to apply now through August 7th for the Lyfebulb-Orexo Innovation Challenge
-
Stem Cells for Everyone: Revolutionizing Regenerative Medicine with Mass Manufacturing of Induced Pluripotent Stem Cells (iPSCs)
7/15/2020
I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette
-
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
7/15/2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary revenue results for the three months ended June 30, 2020. Second Quarter 2020 Preliminary Revenue Summary : Net revenue of between $68.0 million and $68.6 million for the t
-
Newly Published Study Funded by the Alzheimer's Drug Discovery Foundation Finds Dopamine Therapy Improves Cognitive Function in Mild-to-Moderate Alzheimer's Disease
7/15/2020
A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the brain, improves cognitive function in patients with mild-to-moderate Alzheimer's disease.
-
OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2020
7/15/2020
Preliminary Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020